Delivering Evidence to Prevent Recurrent Venous Thromboembolism in Pregnancy

Abstract

(Lancet. 2022;400:1743–1745) Pregnant and postpartum women have an increased risk for venous thromboembolism (VTE) (0 to 1%) with a history of VTE increasing the likelihood (2% to 10%). Hypercoagulability, endothelial damage, and venous stasis are contributing factors. Low–molecular-weight heparin (LMWH) thromboprophylaxis during pregnancy to 6 weeks postpartum is the recommended treatment for women with history of VTE, yet evidence-based dosage recommendations are lacking, causing dosage variation between countries and practices.